Irampanel

Irampanel
Clinical data
ATC code	None
Identifiers
	IUPAC name N,N-Dimethyl-2-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)phenoxy]ethanamine;
CAS Number	206260-33-5
PubChem (CID)	3038472
ChemSpider	2302037
ChEMBL	CHEMBL29741
Chemical and physical data
Formula	C18H19N3O2
Molar mass	309.362 g/mol
3D model (Jmol)	Interactive image
	SMILES CN(C)CCOc1ccccc1c2nc(no2)c3ccccc3 ;
	InChI InChI=1S/C18H19N3O2/c1-21(2)12-13-22-16-11-7-6-10-15(16)18-19-17(20-23-18)14-8-4-3-5-9-14/h3-11H,12-13H2,1-2H3 ; Key:QZULPCPLWGCGSL-UHFFFAOYSA-N ;

Irampanel (INN, code name BIIR-561) is a drug which acts as a dual noncompetitive antagonist of the AMPA receptor and neuronal voltage-gated sodium channel blocker.^[1]^[2] It was under development by Boehringer Ingelheim for the treatment of acute stroke/cerebral ischemia but never completed clinical trials for this indication.^[3]^[4] Irampanel was also trialed, originally, for the treatment of epilepsy and pain, but these indications, too, were abandoned,^[1] and the drug was ultimately never marketed.

References[edit]

^ ^a ^b Feigin V (June 2002). "Irampanel Boehringer Ingelheim". Curr Opin Investig Drugs. 3 (6): 908–10. PMID 12137411.
^ Wang KK, Larner SF, Robinson G, Hayes RL (December 2006). "Neuroprotection targets after traumatic brain injury". Curr. Opin. Neurol. 19 (6): 514–9. doi:10.1097/WCO.0b013e3280102b10. PMID 17102687.
^ Arunabha Ray; Kavita Gulati (1 January 2007). Current Trends in Pharmacology. I. K. International Pvt Ltd. pp. 321–. ISBN 978-81-88237-77-7.
^ Weiser T (April 2005). "AMPA receptor antagonists for the treatment of stroke". Curr Drug Targets CNS Neurol Disord. 4 (2): 153–9. PMID 15857300.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.